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 58 year old male. Decline in work & memory 8 years before HBOT.
 Alzheimer’s diagnosis 5½ years before HBOT; started on Aricept. 
 Continued decline over next 3 years. 
 Failure Neotrophin and Exelon  
 Begins CPAP 1/01 for 10 year history of sleep apnea. Wife notes 
improvement in cognition & behavior.
 89 HBOT treatments in blocks:  5/1/01-9/14/01:
Progressive slow improvement in cognition/behavior.
Generalized improvement in memory scores.
Symptomatically better.
Patient taken off Exelon subsequently due to side effects. 
Periodic HBOT in small doses.  Transient improvement in affect.
Slow deterioration cognitively.
Re-institution of Exelon and additional medications.
Harch PG.  Townsend Letter, April, 2018:417:30-34  
5/1/2001: pre-HBOT
Harch PG.  Townsend Letter, April, 2018:417:30-34  
5/2/2001: post-1 HBOT
Harch PG.  Townsend Letter, April, 2018:417:30-34  
8/6/2001: post-40 HBOTs
Harch PG.  Townsend Letter, April, 2018:417:30-34  
9/14/2001: post-80 HBOTs






Hyperbaric Oxygen Therapy is the 
use of increased…pressure and 
increased oxygen… as DRUGS to 
treat pathophysiologic processes 
of diseases.1
1. HBO Therapy in Global Cerebral Ischemia/Anoxia and Coma.  Chapter 20. 
Textbook of Hyperbaric Med., 6th Edition,  K.K. Jain (Ed.), 2017.
“A Re-appraisal”
The basis of HBOT:




8,101 genes turned on or turned off.
Turned on Genes:








Neurodegeneration corresponds to any pathological condition 
primarily affecting neurons.
Neurodegenerative diseases represent a large group of neurological 
disorders with heterogeneous clinical and pathological expressions 
affecting specific subsets of neurons in specific functional anatomic 
systems; they arise for unknown reasons and progress in a relentless 
manner.  (A disease of neurons).
Does not include those diseases with neuronal death due to known 
causes such as hypoxia, poison, metabolic defects, or infections. 
????
Przedborski S. J Clin Invest, 2003;111(1):3-10
Hundreds of different neurodegenerative 
disorders, the more common of which 
are:
AD, PD, HD, ALS, CTE, Lewy Body Dementia, Prion 
disease, Motor Neuron Disease,Spinocerebellar ataxia, 
Spinal muscular atrophy, cortico-bg degen., FT dementia, 
others.
By 2040 WHO estimates that neurodegenerative diseases 
will be the second leading cause of death after 
cardiovascular disease in developed countries. 1
Katharine Gammon.  Neurodegenerative Disease: Brain Windfall. Nature, 2015:515:299 -300.
Biology:
Apoptosis, oxidative stress, mitochondrial 
dysfunction.1,2
Persistent inf lammation and oxidative stress are crucial 
factors of ongoing cell damage.3
Essentially, Neurodegenerative Diseases are partially 
characterized by persistent wounding.
1. Przedborski S. J Clin Invest, 2003;111(1):3-10
2. Jomova K. Mol Cell Biochem, 2010;345:91-104.
3.  Miller E. Frontiers in Bioscience, Elite, 2017;9:214-234.
Biology:  Reminder
Wounding in the body and central nervous system can 
occur by any number of different insults:  
(ischemia, hypoxia, toxin, mechanical, electrical, etc.)
all of which generate the dominant 
SECONDARY INJURY
(reperfusion injury, inf lammation, edema, ischemia, 
hypoxia)
Etiology:
With few exceptions, the causes of NDD are essentially unknown.  Even when 
identified, the mechanisms…remain, at best, speculative:
Genetic factors:  10% of PD, AD, and ALS are unequivocally familial. 1
For “sporadic” NDD cases, the vast majority of NDD patients, genetic contribution is 
minimal.  Toxic environmental factors may be the prime suspects, but sporadic cases 
may result from a combination of genetic and environmental causes.1
EXAMPLE:  Inhaled particulate matter may significantly contribute to 
neurodegenerative disease through neurotoxic effects (Inf lammation, ROS/oxidative 
stress, disturbance of protein homeostasis/neurotransmitters) 1
1. Przedborski S. J Clin Invest, 2003;111(1):3-10
2. Wang Y. J Applied Toxicology, 2017; (wileyononlinelibrary.com) DOI 
10.1002/jat.3451
Treatment:
For the most part, none.
Symptom modulation.
Minimizing oxidative stress.
Antioxidant and redox therapies:  Vitamin C, Vitamin E, glutathione, 
Lipoic acid, Flavenoids (catechins-green tea, curcumin), ginkgo biloba, 
Coenzyme Q10, selenium, Omega-3 fatty acids, melatonin, cannabinoids, 
physical exercise. 1,2
1. Jomova K. Mol Cell Biochem, 2010;345:91-104.






NDD is caused?/propagated by oxidative stress.
HBOT causes oxidative stress.
Oxidative stress is necessary for the beneficial effects of HBOT. 1
Too much oxidative stress is harmful.
Yet, the net effect of HBOT is reduction of oxidative stress and 
inf lammation.
Solution:
Achieving the right amount of oxidative stress through proper 
dosing of HBOT
1. Thom, SR, et al.   J Neurobiol, 2002;51:85-100.
2.  Poff A, et al. Compr Physiol, 2017;7:213-234.
 The benefits of HBOT are in the proper dosing of oxidative stress 
(Harch, 1998).
 Joseph Priestly, 1774:  “Though pure dephlogisticated air 
(oxygen) might be useful as a medicine, it might not be so proper 
for us in the usual healthy state of the body: for as a candle burns 
out much faster in dephlogisticated than in common air, so we 
might, as may be said, live out too fast and the animal powers be 
too soon exhausted in this pure kind of air.”
Remember:
HBOT Gene Effects:  
1. Godman, et al:  Anti-inf lammatory genes upregulated,
pro-inf lammatory and apoptotic genes down-regulated
2. Kendall, et al:  Inf lammatory and apoptotic genes down-
regulated.
3. Chen, et al:  Neuro-protective and anti-oxidant genes up-
regulated.
Remember:
Multiple studies of HBOT effects on inf lammation, oxidative 
stress, and apoptosis in acute global ischemia/anoxia and 
coma.1
Chronic study:
HBOT effects on degenerative human intervertebral disc cells:  
2.5 ATA/120 mins. qod x 3.
HBOT suppressed inf lammatory signaling and mitochondrial 
apoptotic pathways.2
1. Harch PG.  Chapter 20, Textbook of Hyperbaric Medicine, ed. K.K. Jain. 2017.
2. Niu C-C, et al.  J Orthop Res, 2013;31:204-209.
HBOT Effects on Mitochondrial Function
(A primary biological dysfunction in NDG Dis):
1. Daily hyperbaric oxygen therapy for life improves mitochondrial function 
and delays onset of motor disease in Wobbler mice (ALS model).  Dave 
KR, et al.  Neuroscience, 2003;120:113-120. 2 ATA/60 minutes/d x 30.
2. Oxygen-Induced Mitochondrial Biogenesis in the Rat Hippocampus.  
Gutsaeva DR, et al.  Neuroscience, 2006;137:493-504. 3 or 5 ATA/45 
minutes TDT. 
3. Endurance performance is enhanced by intermittent hyperbaric exposure 
via up-regulation of proteins involved in mitochondrial biogenesis in mice.  
Suzuki J. Physiol Rep. 2017;5(15): e13349, 
https://doi.org/10.14814/phy2.13349.  1.3 ATA air/60 minutes TDT, qd, 
6d/week, x 24. 
Definition:  Dementia is the loss of 
cognitive functioning—thinking, 
remembering, and reasoning—and 
behavioral abilities to such an extent 
that it interferes with a person's daily 
life and activities.1
Types:  Alzheimer’s (60-70%), Vascular 
(25%).2
 1. https://www.cdc.gov/chronicdisease/resources/publications/aag/alzheimers. 
Htm
 2.  Perng C-H.  Psychopharmacology, 2018;235:1571-1580.
 Literature Review:  HBOT in Vascular dementia
9 human studies on vascular dementia, all in inaccessible
Chinese journals.  
Multiple case reports of HBOT in post-CO dementia.
 Cochrane Review, 2012 (Xiao Y, et al. Cochrane Database Syst Rev, 
2012;7:Art. No.: CD009425. 
 Single article:  Wang SP, et al.  Chinese Journal of Physical Med & Rehab, 
2009;31(7):478-80.
 RCT, 64 patients, vascular dementia.
 Donepezil, 5mg qd +/- HBOT: 2 ATA (97% O2)/60 qd x 24 consecutive days, 
6d rest, x 3 or 72 HBOTs
 Measure:  Mini Mental Status and Hasegawa’s Dementia Rating Scale
 Results:  Significant improvement both measures in HBOT group vs. 
Controls (6.2 vs. 3.2 points on MMSE and 7.2 vs. 3.7 points on Hasegawa)
 Cochrane conclusion:  Insufficient evidence to support HBOT as an effective 
treatment for patients with vascular dementia. 
1.  Xiao Y. Cochrane Database of Systematic Reviews, 2012;7:Art. No.: CD009425.  
www.cochranelibrary.com
 Literature Review:  HBOT in Dementia
 Studies with positive results:
 Edwards AE. J Am Geriat Soc, 1974;22:376-379.
 Boyle E. Proc. 5th Int HBO Conf, W.G. Trapp (Eds.), Simon Fraser Univ., Canada, 
1974; pp. 432-438.
 Jacobs EA. J Geriat Psychiatr., 1972;5:107-136.
 Jacobs EA. NEJM, 1969;281:753-57.
 Jacobs EA. Current Psychiatric Therapy, Vol. II, H Masserman (Ed.), Grune and 
Stratton, Phila, 1971: pp. 100-106.
 Jacobs EA. Proc. 5th Int HBO Conf., WG Trapp (Eds.), Simon Fraser University, 
Canada,;1974; pp. 439-445.
 Ben-Yishay Y. NY State J Med, 1973;73:2877-2880.
 Ben-Yishay Y. Proc. 5th Int HBO Conf, WG Trapp (Eds.), Simon Fraser University, 
Canada, 1974; pp. 424-431.
 Ben-Yishay Y. NY State J Med, 1978;78:914-919.
Schmitz GF.  Evaluation of HBOT for Senility. HBO Review, 1981;2(4):231-250.
Literature Review:  HBOT in Dementia
 Studies with negative results:
 Thompson LW. J Gerontol, 1976;31:23-28.
 Raskin, A. Arch Gen Psychiatry, 1978;35:50-56.
 Goldfard AI. J Gerontol, 27:212-217.
 Conclusions: 
 “At the present time there is no basis for claiming that 
hyperbaric oxygen is beneficial in reversing senility or any other 
central nervous system deficit which occurs in the aged.  There 
is a lack of scientifically sound data on this topic.” 
Schmitz GF.  Evaluation of HBOT for Senility. HBO Review, 1981;2(4):231-250.
 Literature Review:  HOWEVER!
 Meta-analysis on treatment of dementia
 Review of literature 2000-2016
 235 studies, 44,854 patients, vascular, Alzheimer’s dementia, 
mild cognitive impairment, and mixed.
 Reviewed 5 types of treatments:
 Antipsychotic drugs and cognitive enhancers
 Symptomatic treatment drugs for Vascular Dementia (piracetam, 
nimodipine, aniracetam, flunarizine, vinpocetine, HBOT, 
oxiracetam, or EGB761). 
 Behavioral therapy (exercise, music, reminiscence, rehab, cog, PT
 Adjunctive therapy (Chinese herbal and medicine, decoctions
 Other alternative treatments:  scalp acupuncture, Premarin, statin, 
butylphthalide soft capsules, donepezil, huperzine A, and lithium
Perng C-H. Psychopharmacology, 2018;235:1571-80.
Literature Review:
 Results:
 Treatment 1 lowest efficacy.
 Treatment efficacy increases with publication year and 
decreases with age of the patient.
 Treatment 2 and Treatment 4 had the highest efficacy for 
treating cognitive dysfunction
 Vascular Dementia patients had the greatest cognitive 
improvement.
 Treatment 2 and Treatment 5 had the highest efficacy vs. 
other treatments (p=.010 and .001) in  relatively young 
patients with vascular dementia.
 Alternative therapies are effective in the treatment of 
dementia. 
Perng C-H. Psychopharmacology, 2018;235:1571-80.
 Lecturer’s personal experience:
 First case in 1995.  
 75 y.o. female, urosepsis/shock in 1992, coma x one week, progressive 
decline in mental function noted by treating physicians, disputed by 
husband. 
 Repetitive falls 1-3/1994 without TBI, RSD LUE due to injury.
 24h nursing care.
 9/1994:  fall, subdural hematoma, accelerated decline in mental status.
 10/1995:  evaluation in New Orleans
 Incontinence, hostility, blind right eye, wheelchair-bound, depressed, disorient, 
blank stare.
 MRI:  8/95:  atrophy + multiple small CVAs (right caudate, corona radiata, internal 
capsule, left occiput).
 Neuropsych testing:  “failed.”
 PMH:  RA, DM.
 Folstein:  11, after 3rd HBOT.
 SPECT, dive, SPECT.
 38 HBOTs, 1.5/60, 11-12/1995, bright, alert, increased ADL’s, Folstein 13
 Lecturer’s personal experience:
 First case in 1995.  
 30 HBOTs 1-3/1996, total 68 HBOTs. peak improvement at 19, total 57, 
mild deterioration afterward.
 Clinically improved:  conversational, not combative, feeding self 
independently, incontinence decreased, diaper frequently dry and 
signals that needs to use bathroom, watching TV and reacting 
appropriately to events/news.
 PEx:  bright alert, follows commands, gets out of chair unassisted, 
unassisted gait.  
 Husband made non-profit donation that funded TBI animal study:  
human protocol of HBOT in chronic TBI, became first and only 
improvement of chronic animal brain injury in history of science.
 Repeat SPECT after 57th HBOT. 







 Four months: nightly confusion, memory loss, paranoia, and inappropriate 
behavior. Removal from grandchildren’s home.
 Three hospital admissions for GI bleed in three months.
 Emergency department visit for dementia and dehydration.
 Deterioration in flight to New Orleans with emergent hospital admission.
 6th hospital admission:  upon arrival inNew Orleans, Dx: dementia and SOB.
PMH:  Long history of alcohol and tobacco abuse with several TBI’s and CO 
exposure (Normal aging?).
 PEx:  Cachectic, SOB elderly man.   Folstein:  15/30. 40 HBOT’s:
 Generalized cognitive improvement
 Increased energy
 Decreased SOB and confusion
 Improved sleep, weight gain.




 Lecturer’s personal experience:
 Subsequent ~70+ cases of cognitive decline or dementia
 All causes: small vessel ischemic disease, post-
surgical/anesthesia, trauma, stroke, toxins, 
Alzheimer’s, multiple cause/premature aging.
 1.15-1.5 ATA/60-90 minutes, qd, 40 treatments, or 
more.
 Functional imaging (SPECT), MMSE, and clinical 
outcomes.
 Best results in small vessel ischemic disease, TBI, 
post-anesthesia, post-chemo, Alzheimer’s.
 Least positive in cortico-basal ganglia degeneration, 
fronto-temporal dementia (Pick’s), Parkinson’s 
(motor findings), multiple systems atrophy. 
 Case Report, Literature Review:
 77 y.o. male, 4.5 y post knee replacement.
 Immediate deterioration post surgery.
 Demented, unresponsive to pharmacotherapy.
 HBOT, 1.75 ATA/60 minutes x 40.  Post 11th HBOT 
weekly perispinal Enbrel (etanercept) for 5 months.
 At the 5 month mark, patient was able to care for 
himself, go on walks by himself, had return of his 
personality, normal sleep cycle, interact with others.
Best S, Pavel DG.  J Medical Case Reports, 2017;11:105, DOI 10.1186/s13256-017-
1259-6.
 Case Report:
 SPECT brain imaging at 5 month mark:
Best S, Pavel DG.  J Medical Case Reports, 2017;11:105, DOI 10.1186/s13256-017-1259-6.
Alzheimer’s Disease Definition: An 
irreversible, progressive brain disorder 
that slowly destroys memory and 
thinking skills, and eventually the 
ability to carry out the simplest 
tasks…the most common cause of 
dementia.1 Closely connected with 
deposition of amyloid beta plaques and 
neurofibrillary tangles in brain tissue.2
1. https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet.
2. Miller E.  Frontiers in Bioscience, Elite, 2017;9:214-234.
 Alzheimer’s Disease Statistics:
 Affects 30 million people worldwide,1 5.4 million in 
U.S.2  Numbers double every 20 y.
 Comprises 60-70% of all dementia.3
 Costs:  $818 billion/y worldwide (1% of global GDP),1
$259 billion/y U.S.2
 Treatment:  largely pharmacotherapy.
 Of 244 drugs tested from 2002-2012, only one with 
FDA approval (Onyango, 2018).4





 Frozza RL. Front Neurosci, 2018;12:37. 
 Single case Report (See above:  Harch, PG, congressional testimony 
2002 and Townsend Letter 4/2018). 
 Recent animal study:
 Shapira: 
 Old mice:  normal and transgenic Alzheimer’s mice.
 Behavioral, histological, and biochemical analyses pre 
and 24-48h post HBOT or the last behavioral task.
 HBOT:  2 ATA/60 minutes qd x 14.
 Results:  HBOT reduced inflammation (decreased 
astrogliosis, microgliosis, IL-1Beta, TNF alpha, and 
increased scavenger receptor A, arginase 1, IL-4 and 10), 
reduced hypoxia,k amyloid burden, and tau 
phosphorylation.  Ameliorated behavioral deficits. 
1. Shapira R. Neurobiology of Aging, 2018;62:105-119.
 Lecturer’s personal experience:
 11 cases since 2001
 Diagnosis by various neurologists
 Nearly all on dementia drugs
 SPECT brain imaging pre/post HBOT on majority
 HBOT at 1.15-1.5 ATA/60 minutes x 40 (most) or 80.
 8 of 11 with clinical and Mini Mental Status improvement.  
 PET imaging pre/post on most recent case:
 Clinical symptomatic improvement
 Improvement in FDG PET:   average 17% global increase.
 Subsequent intermittent treatment over 18 months with maintenance 
of Folstein Mini-Mental Status Score
 Simultaneous use and disuse of Alzheimer’s drugs.
 Parkinson's disease (PD) belongs to a group of conditions called 
motor system disorders, which are the result of the loss of 
dopamine-producing brain cells in substantia nigra. The four 
primary symptoms of PD are tremor, or trembling in hands, 
arms, legs, jaw, and face; rigidity, or stiffness of the limbs and 
trunk; bradykinesia, or slowness of movement; and postural 
instability, or impaired balance and coordination.1
 Pathological characterized as intracellular deposition of alpha-
synuclein (AS) in Lewy Bodies; a soluble protein w/ prion-like 
properties (spreading).2
 Essentially, is a multi-system disorder: CNS & PNS.2
1. http://www.ninds.nih.gov/disorders/parkinsons_disease/parkinsons_disease.htm
2. Borghammer P. Movement Disorders, 2017; Aug 26. doi: 10.1002/mds.27138. [Epub ahead of print]
 However, AS affects an array of different 
neurons, including nigral, cortical, enteric, 
and cardiac neurons.1
 Alpha synuclein deposition in other areas 
of the brain outside the substantia nigra. 
may account for the diverse Sx in PD.2
 Release of AS from neurons and other 
evidence points to possible inflammation 
involvement in the pathogenesis of PD.1
1. Engelender S. Trends in Neurosciences, 2017;40(1):4-14.
2.   Adler CH. Movement Disorders, 2016;31(8):1114-9.
Coronal slices of human brain showing the basal ganglia. White matter is shown in dark 
gray, gray matter is shown in light gray.
Anterior: striatum, globus pallidus (GPe and GPi)






Connectivity of the basal ganglia as revealed 
by diffusion spectrum imaging based on 
thirty subjects from the Human Connectome 
Project. Direct, indirect and hyperdirect
pathways are visualized in different colors 
(see legend). Subcortical structures are 
rendered based on the Harvard-Oxford 
subcortical thalamus as well as the Basal 
Ganglia atlas (other structures). Rendering 





of the basal 
ganglia
Different anatomical areas affected by 
Parkinson’s are subserved by different 
neurotransmitter systems.
The primary neurotransmitter is 
dopamine.
However, there are multiple others. 
The image shows dopaminergic pathways of the human brain in normal condition (left) 
and Parkinsons Disease (right). Red Arrows indicate suppression of the target, blue arrows 
indicate stimulation of target structure. (Ansa lenticularis visible but not labeled, as red 








Diagram shows two coronal slices that 
have been superimposed to include the 
involved basal ganglia structures. Green 
arrows (+) refer to 
excitatory glutamatergic pathways,
red arrows (–) refer to 
inhibitory GABAergic pathways 
and turquoise arrows refer 
to dopaminergic pathways that are 
excitatory on the direct pathway and 




Glutamine, GAB A, 
and Dopamine Path-
ways in the basal 
ganglia
 Heredity-10-15%, remaining 85% are sporadic, all causes:
 Drugs:  MPTP (methyl phenyl tetrahydropyridine), designer drugs 
(Los Angeles outbreak in the 1980s).
 CNS infections
 Heavy metals (Manganese, others)
 Toxins: CO, pesticides, herbicides, Agent Orange, other
 Trauma (Muhammed Ali)
 Ischemia/hypoxia/vascular
 Rural living, well water contamination
Parkinson’s Disease Foundation:http://www.pdf.org/causes#enviro
https://nwpf.org/stay-informed/news/2010/12/toxic-causes-of-parkinsons-disease/
 64 patients, 37-78 years old, 29 men, 35 women
 Duration of illness:  1-15 years, at least 5 yrs. in most 
patients
 Causes:  
 Atherosclerosis:  49 patients
 Atherosclerosis + high blood pressure:  6 patients
 Encephalitis:  8 patients
 Closed head injury:  1
Neretin VY, et al. Neuroscience and Behavioral Phys 1990;20(6):490-2
 Treatment:  HBOT @ 1.3-2.0 ATA/40-60 minutes for 8-12 Rxs.
 “Nootropic medications and preparations involving the 
microcirculation” in all.  37 continued their medications.
 Results:
 1 or two HBOTs caused improvement in general state of feeling in 
all patients.
 Perceptible shifts in neurological status were identified (4-6 Rxs)
 1/3rd of patients:  improvement in mood, cognition, decreased tone 
after 2-3 HBOTs.
Neretin VY, et al. Neuroscience and Behavioral Phys 1990;20(6):490-2
Results:
 Akinetic-rigid had greater response than other 
forms (vascular etiology)
 Good results: 18 patients, remission in 3 of these.
 Satisfactory results:  26 patients.
 Insignificant results:  11 patients.
 Tremulous patients responded to higher dose
Neretin VY, et al. Neuroscience and Behavioral Phys 1990;20(6):490-2
Results:
 No change:  5 patients, however, during HBO and for 
1-3h afterwards, a decrease in the “frozen character 
and severity of tremor” were observed.
 Discontinued treatment:  4 patients (claustrophobia 
and hypertensive crises)
 Results better in vascular Parkinson’s than in the 
encephalitic form
 36 patients maintained improvement for upto six 
months.  The HBOT course was repeated two 
times/year to stabilize the condition.
Neretin VY, et al. Neuroscience and Behavioral Phys 1990;20(6):490-2
 15 patients, 46-85 years old (avg. 65.5), 8 men, 7 
women
 Duration of illness:  6-25 years 
 Causes:  
 Idiopathic:  7 patients
 Vasculopathic:  4 patients
 Encephalitis:  3 patients
 Other:  1
Boromei A.  Procs. of 12th Int. Congr. on Hyper. Med.  Best Publishing Co 
1998
 HBOT:  2 protocols
 Decompensated or complicated, non-vascular:  15 
treatments + 5 treatments q 3 months:  1.9 ATA/80 w 10 
mins./2mins. cycles of O2/air.
 Complicated, vascular causes:  25 treatments + 5 
treatments q 3 months:  2.5 ATA/90 w 10 mins./2 mins. 
O2/air.
 Outcomes measured with Webster Rating Scale (motor) 
and Crichton Geriatric Behavioural Scale (ADLs and 
behaviour).
Boromei A.  Procs. of 12th Int. Congr. on Hyper. Med.  Best Publishing Co 1998
 Results:
 Significant improvement on both scales
 High correlation of the scores on the two scales after 
treatment
 Improvements characterized by improvement in 
motor, mood, and overall function.
 Average 9 month outcome.
Boromei A.  Procs. of 12th Int. Congr. on Hyper. Med.  Best Publishing Co 1998
 45 y.o. man with 1.5 yrs. of progressive tremor, 
bradykinesia, accelerating in past 3 months with 
depression and anxiety.
 Prescribed anti-Parkinson’s meds in past, ineffective, 
refused further meds.
 MRI brain and ultrasound head and neck negative.
 HBOT:  2.0 ATA/80 mins./10 min. air break qd x 30.
 Results:
 After 4 HBOTs:  improved sleep quality and duration 
(from 2-3h to 5h/nite).  Improved mood.
Xu, Jin-Jin. Medicine, 2018;97:9(e0029)..
 At end of HBOT:
 Normal sleep time (8-10h)
 Weight increased by 10kg.
 Tremor and bradykinesia improved significantly.
 One month post:  persistent gains, no need assistance with ADLs.
Xu, Jin-Jin. Medicine, 2018;97:9(e0029)..
 Lecturer’s Experience:  crude recall
 ~10 cases
 HBOT at 1.25-1.5 ATA/60-90 minutes, qd, x 40
 Limited response:
 Minor effect on motor symptoms
 Some improvement on other symptoms of PD:  cognition, affect.
 ? Wrong dose or ineffective for this disease.
Amyotrophic Lateral Sclerosis:  a rare group 
of neurological diseases that results from 
the gradual deterioration and death of 
upper and lower motor neurons that are 







 HBOT:  2 ATA/60 mins., daily, 5d/week, 4 weeks.
 Measure neurological condition serially during 4 wks. of Rx and for 
4 wks. post Rx.
 Results:
 4/5 patients:  decreased fatigue
 Maximum isometric voluntary contraction of all muscle groups except right hand grip 
improved significantly by up to 97%.
 Most improvement occurred during the 4 weeks after treatment.
Steele J.  Amotroph Lateral Scler Other Motor Neuron Disord, 2004;5(4):250-4.
Amyotrophic Lateral Sclerosis:
Phase II “single-blind (patients)” 
controlled study:
 10 patients divided into 2 groups, flip of coin, 1st group HBOT, 2nd
group HBA. 
 HBOT:  2 ATA/60 mins., daily, 5d/week, 8weeks, by hood.  HBA 
group: oscillating pressure to 1.3 ATA/60 mins. by mask.
 Measure neurological condition and muscle strength serially every 
4 wks. up to 20 weeks. 
Steele J.  Amotroph Lateral Sclerosis, 2007;8:274-275. 
Phase II “single-blind (patients)” controlled 
study:
 Results:
 “Some patients in both groups did not complete all the treatments and evaluations due to 
disease-related problems. (1 dropout in HBOT due to non-related injury).
 Data analysis of all HBOT patients and at the 12 week mark for the control group.  No 20 
week followup because HBOT group did not improve.
 Progressive decline in function for HBOT group to 81.5% of baseline muscle function by 
week 20.
 For Control Group decline to 89% of baseline by week 12.
 Improvement in ~20% of muscle groups seen at 8 weeks in both groups.
Conclusion:  Didn’t work, don’t recommend
Lecturer:  Hard to reconcile these results with Phase I study.  Overdose? (20 vs. 40 
HBOTs).
Steele J.  Amotroph Lateral Sclerosis, 2007;8:274-275. 
Kim Cherry Case:
 63 y.o. male diagnosed with bulbar ALS on 11/22/2011.  
 Sx:  problems swallowing, breathing, choking weakness, 
imbalance. 
 Early response to NBO. Then gluten-free diet, supplements, 
ozone Rx, HBOT.  Progressive improvement.  5/2017 stopped 
HBOT and started exercise on oxygen.
 Able to play golf, walk, talk, has good quality of life 6 years 
post-diagnosis. 




 A progressive neuro- degener-
ation characterized by the wide-
spread deposition of hyper-
phosphorylated tau (p-tau) as 
neurofibrillary tangles triggered by repetitive mild traumatic brain injury.1
 Is a pathological diagnosis.
 Originally described clinically in boxers (“punch drunk”) as 
dementia pugulistica. 
 Clinically associated with symptoms of irritability, impulsivity, 
aggression, depression, short-term memory loss and 
heightened suicidality that begins 8-10 years after experiencing 
repetitive mTBI.2
1. McKee AC.  J Neuropathol Exp Neurol, 2009;68:709-35.










 Amyloid beta (red), Paired                                                                                                                       
Helical Filaments of micro-
tubule protein tau (brown).
 First 3 rows:  Alzheimers
 Last 4 rows:  CTE
 Lesions at depths of sulci                                                                                      
and perivascular.
Mckee AC.  Brain, 2013;136(Pt 1):43-64.
 Wounds in the Brain: Mckee AC.  Brain, 2013;136(Pt 1):43-64.   
5,5,10,15,20,35,40, 55 mm Hg
 = 10 - 20 mm Hg
Marx Model of Perfusion Gradient Wound
50, 50, 90, 15, 120 - 350 mm Hg
 = 230 mm Hg
During HBO at 2.4 ATA
5, 15, 25, 40, 55,    55 MM Hg
 = 10 mm Hg
 = 10 - 15 mm Hg
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is a treatment for 
WOUNDS




 CTE:   However!
 There is little doubt that some athletes may suffer from long-term 
adverse effects from multiple sport-related concussions (SRC).
 A cause and effect relationship between concussions and/or contact 
sport participation and CTE (p-tau deposition, that causes the 
clinical syndrome) has not yet been demonstrated.
 No compelling empirical evidence to indicate that SRC or 
subconcussive impacts are the sole and direct cause of psychiatric 
illness, suicide, MCI, or neurodegenerative disease/CTE.
 Must account for genetic, medical, psychiatric, substance abuse, and 
biopsychosocial variables.
Solomon G. Develop Neuropsychol, 2018;43(4):279-311
Early case experience
(New Orleans and Slidell, LA)
1.  Gratuitous neurological improvement in extremity wound 
patients with chronic neurological diagnoses.
2. Divers with subacute cerebral decompression illness.
3. Louisiana boxers:  Dementia Pugulistica Study:
a. Community Hospital IRB
b. Funded by The Hirsch Foundation ($20,000) to Keith Van 
Meter, M.D. and Sheldon Gottlieb, Ph.D. of the 
Baromedical Research Foundation of New Orleans.






Boxing 15-32 y.o., 15 years professionally
135 professional bouts, last one 23 years before HBOT
World champion
1 LOC in 1st 100 bouts, 4 LOCs in last 5 fights, last LOC 
x 3-5 mins. 
Subsequent 10 years casino work with declining ability 
(Black Jack…roulette wheel… shuffle cards… fired)
Paranoia begins 2 years after last bout, eventual 
hallucinations.
Diagnosis:  Paranoid schizophrenia, supervised care by 
family, able to dress and feed self.
Meds:  Artane 2mg tid, Ativan 2 mg tid, Stelazine 2mg bid, 
occasional Percodan, Soma.
PEx:  Conversant, suspicious, skulking panther like 
movements (basal ganglia injury?)
Slow speech, disoriented, abnormal balance and gait.
Slow speech.  Poor short and long-term memory.  
Neuropsychological testing:  Marked global impairment 
with many tests in the 1-2% ile range.
SPECT, pre and post 1 HBOT (1.75 ATA/65):
Marked decrease in blood flow bilateral 
temporal lobes (R worse) and less so frontal 
lobes and right parietal lobe.  Post HBOT 
marked increase in flow to the right TL, 
normalization of FLs and right PL.
MRI, brain:  Moderate central and cortical 
atrophy, right occipital WM infarct and area 
of porencephaly.
HBOT:
10/1991-3/1992:  1.75 ATA/65 mins. x 1
1.5  ATA/65 mins. x 20
3 week break
1.75 ATA/70 mins. x21 (42
HBOTs)
3 week break
2.0 ATA/70 mins. x 21 (63
HBOTs)
Confusion, decreased memory, imbalance, 
shakiness during 1st 15 HBOTs.
HBOT:
Improved Symptoms:  16-20 HBOTs
21-42 HBOTs
43-63 HBOTs
Repeat SPECT hours post:
21st HBOT, at 1.5 ATA
42nd HBOT, at 1.75 ATA





Repeat PEx:  Faster, more fluent speech, less 
paranoia, improved mood, energy, gait, balance.  
Family impressed with change in persona.  Brother 
(former boxer) upset that he could not get 
treatment for his deficits.
Repeat NP testing:  improvement in multiple 
domains, but only small improvement in %ile
ranking.  Patient was more oriented, knew for the 
first time on final testing why he was there, and the 
purpose of the testing.  
Case Presentation #2
 Tom Dempsey, 64 y.o. retired
NFL player (permissions granted).
 6 concussions that he can count, 
but only remembers 3, none with 
LOC:  1969, 1971, and 1974. 
 Each with confusion, HA, disorientation, played rest of game, 
symptoms lasted 1 week. 
 Retired 1979.  By 2008 developed irritability, mood disturbance 
with flashes of irrational anger.  Significant alcohol intake, 
previous chewing tobacco, steroid use once.  (Solomon article!)










 PMH:  DM, Meds:  supplements, Metformin, Glipizide, 
Lisinopril, Pravastatin.
 FH:  dementia in two aunts manifest in their 50s.
 Neuro ROS:  snoring (no evidence OSA pattern), dizzy in 
heat, poor enunciation, decreased balance, general cognitive 
decline, decreased energy level, mood swings, irritability.
 PEx:  deformities of right hand and foot, positive glabella and 
snout, poor tandem gait, bradykinesia.
 SPECT:  3-D only—abnormal bilateral TLs, orbital FLs, and 
high parietal watershed areas.
 Folstein MMSE:  24  
http://www.theadvocate.com/new_orleans/sports/saints/article_57cb7d51-2847-50a2-bf82-e6b6c1577d07.html
MicroCog Assessment 2011
qEEG TBI Discriminant Analysis 2011
SPECT 3-D Surface Reconstruction 5/23/2011
SPECT Cage View Reconstruction 5/23/2011
Case Presentation:  Tom Dempsey
 HBOT:  1.4 ATA/60, qd, x 40, 5-7/2011.
 Re-Eval:
 Mixed result.  Early symptomatic improvement.  Disappointed 
later:  pt. was hoping for big improvements.
 Started driving again at times.
 Mild improvement balance, memory at times, energy level
 Could retell his stories better.
 PEx:  balance worse.
 Folstein decreased to 21-22 (off by 1 day on date).
http://www.theadvocate.com/new_orleans/sports/saints/article_57cb7d51-2847-50a2-bf82-e6b6c1577d07.html
Case Presentation:  Tom Dempsey
 In the months following HBOT, improvement.
 1/2013, 18 months post HBOT:  “clearcut improvement.”  
Sustained driving.  Getting after-care through Tulane Sports 
Medicine Program.
 Later 2013, 24 months post HBOT:  “nosedived.”  Continued 
after-care.  Wife unable to care for patient.  Put in nursing 
home.  Slow progressive decline.
 5/5/2018:  in nursing home, total dependence, can’t feed self,  
“doesn’t know how to walk.” Jeri-chair.  “Doesn’t recognize 
anyone. “ Physically healthy.  
http://www.theadvocate.com/new_orleans/sports/saints/article_57cb7d51-2847-50a2-bf82-e6b6c1577d07.html
Case Presentation:  Tom Dempsey
 Conclusion:
 Initial response to HBOT with more noticeable improvement in 
months after treatment (Dose implications?).
 No further HBOT.
 Sustained benefit of HBOT, coupled with additional PT and 
stimulation.
 Precipitous decline.
 Alive, healthy, late stage dementia.
http://www.theadvocate.com/new_orleans/sports/saints/article_57cb7d51-2847-50a2-bf82-e6b6c1577d07.html
Case Presentation #3
Retired NFL linebacker; 46 years old
cc:  Wants to preserve brain, scared of appearance of old friends, is 
tired, gets punchy after airplane flights.
Played football from 10-37 y.o., professionally for 16 years.  Tackled 
with head.
22 documented concussions, one with LOC.  Remembers “seeing 
stars” at least once/game or practice for entire career.
Steroid use throughout professional career, “always on some 
anabolic stimulant.”  Stimulants every year of professional football.
Transient effects of concussions became permanent with 
simultaneous increasing fatigue. 
Contacts PGH, M.D. 2000-2001 football season:  had been using 
HBOT (hardshell and portable) and was “exhausted,”  couldn’t finish 
season.
Recommendations to use HBOT for recovery and head injuries 
instead of performance enhancement.
Case Presentation
Finished 2000-1 and 2001-2 seasons and was symptomatically 
improved.
 Traded to another team in 2002.  No HBOT.  Concussions 
accumulate, increasing toll, unable to play due to neuro Sx, 
confusion after away game in 2003.  Couldn’t travel home.
Extensive workup:  NP, MRI.  ? Results.  Sx improve over time.
Repeat CT, MRI, EEG in 2006 @ U. of Pittsburgh-normal.
Neuro ROS:  STM problems, short-temper, irritable, avoids crowds, 
commotion, low energy level, decreased smell, taste, generalized 
cognitive decline
PMH:  testosterone, Arimedex (increases testosterone), vitamins, 
apnea in sleep, 500 mg caffeine/day
FH:  addiction, Alzheimer’s in mother, two others with Alzheimer’s, 
EtOH, depression.  (Solomon article!)
PEx:  balance and coordination findings.
SPECT, single HBOT at 1.4 ATA/50, repeat SPECT
Improved vision, energy level, thinking clearer, feels better post 
single treatment. 
35 additional HBOTs, 1.4/50, qd, 5d/week.  IV glutathione and 
phosphatidyl choline, and NAC pre-HBOT, tiw.
Re-Eval:  improved on nearly all symptoms and PEx findings.  
Noted by wife and employees.
Repeat SPECT, 4/2013:  improved.
One month later, Sx regression.  Doing multiple therapies.  No PCP 
F/U.
One month later, 15 additional HBOTs.  Improved.  Continued 
treatment…..exhaustion, headaches.  Stopped HBOT.  Rebound. 
One month later, restart HBOT, additional 19 HBOTs, improved 
until last 10, deterioration.
Evaluation 2 weeks later, overall improvement:  focus, memory, 
reading, energy level, mood control.  PEx:  ~same as post 36 HBOTs.
Repeat SPECT, 8/2013:  slight deterioration compared to post 36 
treatments. 
What does a normal 
person look like on 
brain blood flow 
scanning?
Normal 34 year old male:  LSU IRB 1998-2001
Purportedly Normal 34 year old male:  LSU IRB 1998-2001
Normal 34 year old male:  LSU IRB 1998-2001
Purportedly Normal 34 year old male:  LSU IRB 1998-2001
Normal 34 year old male:  LSU IRB 1998-2001











5/12/2018: Patient remains active 
in his multiple businesses, has 
sponsorship by a national 
corporation, and hosts a radio 
show.
? Additional HBOT
 Literature Review:  Single publication
 Stoller, Medical Gas Research, 2011;1:17: 1 of 2 cases:
 “In his early 50’s”, retired NFL player.
 mTBI w/LOC Pop Warner football-youth
 Numerous concussions through football career (high school, 
University of Colorado).
 2nd ”major” concussion during 1st play in NFL, San Francisco 
49ers.
 25-30 smelling salts to finish game.
 2nd season, concussion, headache, multiple evaluations by 
team trainer and physician.  Pain pills.
 Increasing headaches.
 Stoller, Medical Gas Research, 2011;1:17 
 2nd season, 
 Hydrocephalus.
 Emergency VP shunt.
 11 subsequent shunt revisions over 9 years.
 19 years later (2009) undergoes 40 HBOTs at 1.5 ATA/60 
minutes for ?Sx.
 MicroCog assessment pre/post HBOT (improvement on 
5/6 indices).
 SPECT brain imaging pre/post HBOT (improved on 
surface 3-D reconstruction).
 Stoller, Medical Gas Research, 2011;1:17 
 SPECT surface 3-D pre/post HBOT:
Pre-HBOT Post-HBOT
 Conclusions:
 CTE is a pathological condition resulting from multiple 
traumatic wounds of the brain, possibly in combination with 
other insults, that is associated with a multi-domain clinical 
condition.
 HBOT is a treatment for wounds in any location and of any 
duration
 Limited case experience with HBOT in CTE.
 Encouraging outcomes with HBOT in CTE consistent with 
HBOT treatment of other chronic cerebral wounding 
conditions, such as persistent post-concussion syndrome.
 58 y.o. Caucasian female with cognitive decline over 8 months
 Extensive workup negative: blood work, MRI, MRA, bubble-
contrast TTE, PVD study, abdominal ultrasound, 24h Holter 
monitor, carotid ultrasound.
 EEG:  diffuse slowing.
 APOE:  homozygous e3.
 Abnormal neuropsychological testing.
 Abnormal PET.
 PMH:  
 natural gas exposure/syncope 9 y.o.
 Childhood exposure oil refineries, metallurgy plant.
 10 year work exposure to mold post Hurricane Katrina
 Lifelong hypotension.
 FH:  brother with dementia secondary to TBI (concussions, boxing), 
drug abuse, ECT.
 PEx:  abnormal:
 slight tremor, decreased pinprick bilateral face, instability on deep 
knee bend, decreased pinprick in distal 4 extremities, diffuse 
hyperreflexia, trouble following directions, tandem gait, 
disdiadokinesis, Romberg, finger-to-nose.
 Patient refused all medications except Lexapro, Biotin, Vitamins 
B12 and D three weeks pre-HBOT.
 HBOT:  forty 1.5 ATA/50 minutes total treatment time, once/day, 
5d/week HBOTs in 66d.
 After 21 HBOTS patient reported symptomatic improvement with 
increased energy/activity level, mood, ability to draw a correct 
clock face, perform activities of daily living, and work crossword 
puzzles. 
 Neurologist started Exelon patch 9.5 mg for one week:  
discontinued by patient.
 At completion of 40 HBOTs patient reported
 increased memory and concentration, not getting lost as 
frequently, resolution of anxiety, improved sleep, ability to use 
the computer, more good days (5/7) than bad days, better 
conversation, less frustration, increased appetite.  
 Tremor, deep knee bend, tandem gain, motor speed were 
improved. 
 Repeat PET one month post HBOT showed global improvement in 
brain metabolism.
 Two months post-HBOT patient felt a regression in her 
symptoms.  Exelon was begun at 9 mg, increased to 12, then 
decreased to 9 to GI intolerance.
 After 4 weeks Exelon was discontinued due to no 
improvement in symptoms.  
 Four months post HBOT patient had repeat NP testing 
which showed improvement in some scores, no change in 
many, and worsening of many.  
 Over the 18 months post NP testing patient has received 61 
HBOTs.
 Folstein Mini-Mental status during this time is as follows:
 1/17/17:  22.  Oxygen concentrator, 3x/wk x few weeks before this date.  
Restart Exelon patch 2/2017.
 5/12/17:  23. 70 HBOTs by this date.
 8/28/17:  23. Exelon, oxygen concentrator.
 2/7/18:  19.  88 HBOTs.  Off Exelon x 2d.  Start Donepezil, 5 mg/day.
 6/21/18:  22.  96 HBOTs.
 Conclusion:
 HBOT generated a diffuse increase in brain 
metabolism, including the signature areas responsible 
for Alzheimer’s Disease.
 This implies an HBOT effect on more than just acetyl 
choline pathways.
 Simultaneously, the patient experienced an 
improvement in symptoms and physical exam.
 The HBOT effect was sustained with additional HBOT 
and medications. 
 Neurodegenerative Disorders have many causes.
 Many of the causes of ND result in wounding of the brain.
 Persistent inflammation is crucial in the pathogenesis of ND.
 HBOT is a reparative treatment for wounds.
HBOT is anti-inflammatory.
 HBOT dosing is a matter of matching the dose of pressure and 
oxygen to the pathological targets in the disease. 
 The literature on HBOT in ND is not substantial, but sufficient 
enough to suggest that HBOT has a place in the treatment of ND, 
especially dementia.

